Biocon to produce Cuban drug for Covid-19 patients in India.

 

 

 

 

 

Biocon, India’s largest biopharmaceutical company, highlighted on Wednesday the production of the drug Itolizumab, developed by the Cuban Center of Molecular Immunology to treat seriously ill Covid-19 patients.

Biocon recently obtained approval from the Drugs Controller General of India to produce Itolizumab (ALZUMAb), which is used to treat plaque psoriasis, for emergency use in India in moderate to severe Covid-19 patients.

Itolizumab is a molecule that was developed by the Havana-based Center of Molecular Immunology to treat lymphomas and leukemia.

National Award of the Cuban Academy of Sciences in 2014, the humanized monoclonal antibody is part of the protocol established in the country to treat Covid-19 patients.

With this drug, 60% of severely and critically ill patients regain lung function and survive the disease.

(Prensa Latina)
Categorías: Uncategorized | Etiquetas: , , , , , , , | Deja un comentario

Navegador de artículos

Deja una respuesta

Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Salir /  Cambiar )

Google photo

Estás comentando usando tu cuenta de Google. Salir /  Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Salir /  Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Salir /  Cambiar )

Conectando a %s

A %d blogueros les gusta esto: